Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & Administrative
Others
Ratios

Immuneering (IMRX) EBITDA (2020 - 2024)

Immuneering (IMRX) has 5 years of EBITDA data on record, last reported at -$18.1 million in Q4 2024.

  • For Q4 2024, EBITDA fell 19.68% year-over-year to -$18.1 million; the TTM value through Dec 2024 reached -$61.0 million, down 14.21%, while the annual FY2024 figure was -$61.0 million, 14.21% down from the prior year.
  • EBITDA reached -$18.1 million in Q4 2024 per IMRX's latest filing, down from -$14.6 million in the prior quarter.
  • Across five years, EBITDA topped out at -$3.6 million in Q2 2020 and bottomed at -$18.1 million in Q4 2024.
  • Average EBITDA over 5 years is -$11.2 million, with a median of -$12.6 million recorded in 2023.
  • Peak YoY movement for EBITDA: tumbled 121.47% in 2021, then rose 1.7% in 2023.
  • A 5-year view of EBITDA shows it stood at -$5.8 million in 2020, then tumbled by 85.55% to -$10.8 million in 2021, then fell by 21.28% to -$13.1 million in 2022, then fell by 14.9% to -$15.1 million in 2023, then fell by 19.68% to -$18.1 million in 2024.
  • Per Business Quant database, its latest 3 readings for EBITDA were -$18.1 million in Q4 2024, -$14.6 million in Q3 2024, and -$14.1 million in Q2 2024.